AbbVie and CytomX Therapeutics Inc. entered into a collaboration to co-develop Probody Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Under the agreement, CytomX...
For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
